Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
Sionna Therapeutics, Inc. (SION)
Company Research
Source: GlobeNewswire
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced initiation of the PreciSION CF Phase 2a proof-of-concept (POC) trial evaluating SION-719, a first-in-class nucleotide binding domain 1 (NBD1) stabilizer, when added to Trikafta® (elexacaftor/tezacaftor/ivacaftor), the current standard of care (SOC) in CF. “The NBD1 domain of the CFTR protein plays a critical role in the folding, stability and trafficking of CFTR to a cell’s surface, but none of the currently approved CF therapies directly stabilize NBD1. We are thrilled to initiate the first c
Show less
Read more
Impact Snapshot
Event Time:
SION
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SION alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SION alerts
High impacting Sionna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SION
News
- Sionna Therapeutics Valuation Topping $2 Billion Is 'Too Optimistic', RBC Says [Yahoo! Finance]Yahoo! Finance
- Sionna Therapeutics (NASDAQ:SION) had its "underperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $24.00 price target on the stock.MarketBeat
- Sionna Therapeutics to Participate in Upcoming December Investor ConferencesGlobeNewswire
- Sionna Therapeutics (NASDAQ:SION) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Sionna Therapeutics (NASDAQ:SION) was upgraded by analysts at BTIG Research to a "strong-buy" rating.MarketBeat
SION
Earnings
- 11/5/25 - Beat
SION
Sec Filings
- 12/5/25 - Form 144
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- SION's page on the SEC website